The California insurance commissioner, who has spoken out against other large healthcare mergers, this week asked the Department of Justice (DOJ) to block the $69 billion deal combining Aetna with CVS Health.
The California insurance commissioner, who has spoken out against other large healthcare mergers, this week asked the Department of Justice (DOJ) to block the $69 billion deal combining Aetna with CVS Health.
In his letter to Attorney General Jeff Sessions, Dave Jones cited several areas of concern and said the proposed deal is anticompetitive, and, if allowed to go through, would forever end the ability of pharmacy benefit managers (PBMs) to operate as single entities in the state.
CVS owns the PBM Caremark, and the merger will substantially enhance market concentration and power in the PBM space, as well as Medicare Part D markets, he said.
A merger of this size and type will likely lead to increased prices and decreased quality, he said, citing experts on health insurer and healthcare mergers.
In addition, a partial sale or other remedies traditionally used by the DOJ will not go far enough to protect the public or address the adverse consequences, such as charging excessive rates, or the “creation of barriers to block a potential market participant with the resources to enter into new markets,” he wrote.
The merger will eliminate Aetna as an important potential competition in the PBM market. In the present health insurance and healthcare markets, it is impossible to create from scratch a PBM competitor capable of being on the same level as Aetna, he wrote.
“If there are any other entities considering entry into the PBM market, they will now have to enter the market in conjunction with a health insurer,” Jones said.
Jones said that 2 years ago, he was in favor of blocking the Anthem and Cigna merger, which ultimately was not approved, as well as the Aetna and Humana merger. As insurance commissioner, he said he imposed “stringent requirements” on the combination of Centene and HealthNet.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
ACA Dependent Coverage Extension and Young Adults’ Substance-Associated ED Visits
September 15th 2025This study examines the impact of the Affordable Care Act (ACA) on substance-associated emergency department (ED) visits among young adults, revealing reduced alcohol-associated visits but unchanged opioid-associated visits.
Read More